BG
SRPT icon

BlackRock Group’s Sarepta Therapeutics SRPT Stock Holding History

BlackRock Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$12.6M Buy
460,568
+48,499
+12% +$1.95M 0.01% 882
2016
Q3 		$25.3M Buy
412,069
+334,842
+434% +$10.1M 0.01% 738
2016
Q2 		$1.47M Buy
77,227
+53,332
+223% +$988K ﹤0.01% 1746
2016
Q1 		$467K Buy
23,895
+5,404
+29% +$94.4K ﹤0.01% 2268
2015
Q4 		$713K Sell
18,491
-98,761
-84% -$3.2M ﹤0.01% 2056
2015
Q3 		$3.77M Buy
117,252
+105,084
+864% +$3.57M ﹤0.01% 1200
2015
Q2 		$371K Buy
12,168
+2,225
+22% +$45.5K ﹤0.01% 2371
2015
Q1 		$132K Buy
9,943
+1,812
+22% +$24.2K ﹤0.01% 2597
2014
Q4 		$118K Buy
8,131
+3,106
+62% +$52.6K ﹤0.01% 2638
2014
Q3 		$106K Sell
5,025
-1,013
-17% -$22.9K ﹤0.01% 2577
2014
Q2 		$180K Sell
6,038
-14,812
-71% -$468K ﹤0.01% 2481
2014
Q1 		$501K Buy
20,850
+3,995
+24% +$102K ﹤0.01% 2235
2013
Q4 		$344K Buy
16,855
+3,235
+24% +$96.1K ﹤0.01% 2309
2013
Q3 		$643K Buy
13,620
+908
+7% +$35K ﹤0.01% 2126
2013
Q2 		$484K Buy
+12,712
New +$455K ﹤0.01% 2060

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Group's SRPT Position: Q4 2016 in Review

BlackRock Group increased its Sarepta Therapeutics (SRPT) stake by 12% in Q4 2016, buying an estimated $1.95M and bringing the position to 460,568 shares worth $12.6M. The position accounts for 0.01% of the portfolio, ranked #882.

BlackRock Group first reported a position in SRPT in Q2 2013 and has held it in 15 quarters since. The position peaked at $25.3M in Q3 2016. 177 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • BlackRock Group held 460,568 shares of Sarepta Therapeutics worth $12.6M as of Q4 2016.
  • BlackRock Group bought 48,499 Sarepta Therapeutics shares in Q4 2016, an estimated $1.95M.
  • Sarepta Therapeutics made up 0.01% of BlackRock Group's portfolio in Q4 2016, its #882 holding.
  • BlackRock Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Sarepta Therapeutics position peaked at $25.3M in Q3 2016.
  • 177 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.